SNDX — Syndax Pharmaceuticals, Inc.

Is SNDX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Syndax Pharmaceuticals, Inc. (SNDX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $9.13. The rating moved from Strong Oversold to Oversold on November 9, 2026.

See all oversold Healthcare stocks →

AI analysis

Syndax Pharmaceuticals, Inc. (SNDX) is a small-cap, pipeline-centric biotech whose near-term value is driven by clinical outcomes, partnership opportunities, and balance-sheet adequacy. With no broad commercial franchise supporting recurring revenue, the company remains exposed to binary clinical and regulatory events and to dilution risk if additional capital is required. Sector dynamics — including large-cap pharma appetite for specialty assets and ongoing consolidation — provide a plausible upside channel through M&A or licensing, but current market risk-off sentiment and limited public information raise the hurdle for sustained appreciation absent a clear catalyst. Monitor upcoming data milestones, cash runway disclosures, and any partner/transaction activity as primary determinants of the stock’s directional path.

Key factors

  • Pipeline- and data-driven valuation: company value is heavily dependent on clinical readouts and regulatory progress for lead candidates
  • Limited commercial footprint: no significant marketed products to provide predictable revenue; reliance on trial success or partnerships
  • Potential M&A interest in specialty oncology assets amid large-cap pharma consolidation, which could create takeover premium scenarios
  • Balance sheet and cash runway are material drivers; need for capital raises would dilute equity if trials continue without partnering/licensing
  • Biotech sector risk-off environment in short term reduces likelihood of sustained upside absent clear near-term catalysts
  • Low social and EDGAR transparency in the provided window increases information asymmetry and investor uncertainty

Risks

  • Clinical trial failure or negative intermediate/primary endpoint that materially reduces asset value
  • Cash burn and financing risk leading to dilutive equity raises or unfavorable partnership terms
  • Regulatory setbacks or delays in approvals that push out value realization
  • Low liquidity and high share-price volatility typical of small-cap biotech stocks
  • Competitive risk from larger pharma or other biotechs with superior data or commercial capability
  • Adverse macro/market conditions and risk-off flows that pressure speculative biotech valuations
  • Unfavorable licensing or partnering dynamics that reduce potential milestone or upfront receipts

See today's live rating, score and targets

Members see the live hourly rating for SNDX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.